Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

被引：184

作者：

Amatu, A. ^{[1
]}

Sartore-Bianchi, A. ^{[1
,2
]}

Bencardino, K. ^{[1
]}

Pizzutilo, E. G. ^{[1
,2
]}

Tosi, F. ^{[1
,2
]}

Siena, S. ^{[1
,2
]}

机构：

[1] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Dept Hematol & Oncol, Piazza Osped Maggiore 3, I-20162 Milan, Italy

[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

基金：

欧盟地平线“2020”;

关键词：

TRK; tropomyosin receptor kinase; NTRK gene fusions; TRK fusion cancer; NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESOBLASTIC NEPHROMA; TARGETED THERAPY; CONGENITAL INSENSITIVITY; INHIBITOR ENTRECTINIB; PROTOONCOGENE PRODUCT; ACQUIRED-RESISTANCE; HIGH-FREQUENCY;

D O I：

10.1093/annonc/mdz383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and paediatric tumours, providing actionable targets for targeted therapy. This review describes the normal function and physiology of TRK receptors and the biology behind NTRK gene fusions and how they act as oncogenic drivers in cancer. Finally, an overview of the incidence and prevalence of NTRK gene fusions in various types of cancers is discussed.

引用

页码：VIII5 / VIII15

页数：11

共 50 条

[21] Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
Hsiao, Susan J.
Zehir, Ahmet
Sireci, Anthony N.
Aisner, Dara L.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (04): : 553 - 571
[22] Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers (Vol 11, pg 355, 2021)
Jiang, Tingting
Wang, Guan
Liu, Yao
Feng, Lu
Wang, Meng
Liu, Jie
Chen, Yi
Ouyang, Liang
ACTA PHARMACEUTICA SINICA B, 2022, 12 (06) : 2963 - 2964
[23] Clinical and genomic characteristics of tropomyosin receptor kinase (TRK) fusion cancer in community oncology practice
Klink, Andrew
Kavati, Abhishek
Antoine, Ruth
Gassama, Awa
Kozlek, Tom
Gajra, Ajeet
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[24] Pan-TRK Protein Expression and NTRK Gene Fusions in Primary Malignant Tumors of the Liver
Liao, Xiaoyan
Zhang, Dongwei
LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1131 - 1132
[25] Pan-TRK Protein Expression and NTRK Gene Fusions in Primary Malignant Tumors of the Liver
Liao, Xiaoyan
Zhang, Dongwei
MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1131 - 1132
[26] Dysregulated tropomyosin receptor kinase (Trk) signalling in CYLD mutant tumours
Rajan, Neil
Elliott, Richard
Lord, Christopher
Clewes, Oliver
Burn, John
Sieber-Blum, Maya
Ashworth, Alan
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S76 - S76
[27] Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
Schirrmacher, Ralf
Bailey, Justin J.
Mossine, Andrew V.
Scott, Peter J. H.
Kaiser, Lena
Bartenstein, Peter
Lindner, Simon
Kaplan, David R.
Kostikov, Alexey
Fricker, Gert
Mahringer, Anne
Rosa-Neto, Pedro
Schirrmacher, Esther
Waengler, Carmen
Waengler, Bjoern
Thiel, Alexander
Soucy, Jean-Paul
Bernard-Gauthier, Vadim
PHARMACEUTICALS, 2019, 12 (01)
[28] Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan
Nakata, Eiji
Osone, Tatsunori
Ogawa, Toru
Taguchi, Tomoyuki
Hattori, Kana
Kohsaka, Shinji
CANCER MEDICINE, 2024, 13 (12):
[29] Targeting Tropomyosin-receptor Kinase Fused Gene in Cancer
Chen, Yun
Tseng, Sheng-Hong
ANTICANCER RESEARCH, 2014, 34 (04) : 1595 - U620
[30] CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN TRK-B TYROSINE KINASE RECEPTOR GENE (NTRK2)
NAKAGAWARA, A
LIU, XC
IKEGAKI, N
WHITE, PS
YAMASHIRO, DJ
NYCUM, LM
BIEGEL, JA
BRODEUR, GM
GENOMICS, 1995, 25 (02) : 538 - 546

← 1 2 3 4 5 →